The Technical Analyst
Aura Biosciences, Inc. [AURA]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Aura Biosciences, Inc. Price, Forecast, Insider, Ratings, Fundamentals & Signals
Current Signal: SELL (auto-tracking)
-3.17% $7.03
America/New_York / 17 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 348.02 mill |
| EPS: | -1.930 |
| P/E: | -3.64 |
| Earnings Date: | May 06, 2024 |
| SharesOutstanding: | 49.50 mill |
| Avg Daily Volume: | 0.183 mill |
| RATING 2024-04-17 |
|---|
| B- |
| Sell |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Neutral | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Sell | |
| DE: | Neutral | |
| P/E: | Sell | |
| Price To Book: | Neutral |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -3.64 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.62x |
| Company: PE -3.64 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$0.543 (-92.27%) $-6.49 |
| Date: 2024-04-17 |
| Expected Trading Range (DAY) |
|---|
|
$ 6.53 - 7.53 ( +/- 7.08%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-04-02 | Kilroy Conor | Buy | 144 000 | Stock Option (Right to Buy) |
| 2024-04-02 | Kilroy Conor | Buy | 96 000 | Common Stock |
| 2024-04-01 | Kilroy Conor | Buy | 0 | |
| 2024-03-15 | Plavsic Mark | Sell | 0 | Common Stock |
| 2024-03-15 | Plavsic Mark | Sell | 138 000 | Stock Option (Right to Buy) |
| INSIDER POWER |
|---|
| 86.98 |
| Last 96 transactions |
| Buy: 15 662 380 | Sell: 3 253 163 |
Forecast:
16:00 - $7.03
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $7.03
Forecast 2: 16:00 - $7.03
Forecast 3: 16:00 - $7.03
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $7.03 (-3.17% ) |
| Volume | 0.138 mill |
| Avg. Vol. | 0.183 mill |
| % of Avg. Vol | 75.67 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For AURA
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % | Feb 8 - 15:34 | sell | $8.04 | N/A | Active |
|---|
AURA
Aura Biosciences, Inc. operates as a biotechnology company that develops therapies to treat cancer. The company develops virus-like drug conjugates (VDC) technology platform for the treat tumors of high unmet need in ocular and urologic oncology. It develops AU-011, a VDC candidate for the treatment of primary choroidal melanoma. It also develops AU-011 in additional ocular oncology indications, including choroidal metastases. The company was incorporated in 2009 and is headquartered in Cambridge, Massachusetts.
Latest Press Releases
2024-03-27 07:00:00 - Press Release
Aura Biosciences Reports Fourth Quarter And Full Year 2023 Financial Results And Business Highlights
Boston--(business wire)--aura biosciences, inc. (nasdaq: aura), a clinical-stage biotechnology company developing precision immunotherapies to treat solid tumors to preserve the function of the afflicted organ with cancer, today reported financial results for the fourth quarter and year ended december 31, 2023, and provided recent business highlights. “we're excited to expand bel-sar into bladder cancer, as we leverage our therapy's unique mechanism of action in additional solid cancer indicati.
2024-02-26 07:00:00 - Press Release
Aura Biosciences To Participate In Upcoming Investor Conferences
Boston--(business wire)--aura biosciences inc. (nasdaq: aura), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (vdc) therapies for multiple oncology indications, today announced that elisabet de los pinos, phd, chief executive officer, will participate in the following upcoming investor conferences: 44th annual td cowen health care conference on monday, march 4, 2024. fireside chat at 1:30 p.m. et. leerink partners global biopharma conference on tues.
2023-12-07 08:00:00 - Press Release
Aura Biosciences Announces First Patient Dosed In Global Phase 3 Compass Trial Evaluating The Safety And Efficacy Of Belzupacap Sarotalocan (bel-sar) For First-line Treatment Of Early-stage Choroidal Melanoma
Boston--(business wire)--aura biosciences inc. (nasdaq: aura), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (vdc) therapies for multiple oncology indications, today announced the first patient has been dosed in the global phase 3 compass trial evaluating the safety and efficacy of bel-sar for the first-line treatment of adult patients with early-stage choroidal melanoma. “dosing of the first patient in this global phase 3 trial is a major mileston.
2023-11-08 07:00:00 - Press Release
Aura Biosciences To Participate In Upcoming Investor Conferences
Boston--(business wire)--aura biosciences inc. (nasdaq: aura), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (vdc) therapies for multiple oncology indications, today announced that elisabet de los pinos, phd, chief executive officer, will participate in the following upcoming investor conferences: jefferies london healthcare conference on wednesday, november 15, 2023. presentation at 9:30 a.m. et. 6th annual evercore isi healthconx conference on we.
2023-11-06 22:02:00 - Press Release
Aura Biosciences Announces Pricing Of Public Offering Of Common Stock
Boston--(business wire)--aura biosciences, inc. (“aura”) (nasdaq: aura), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (vdc) therapies for multiple oncology indications, today announced the pricing of an underwritten public offering of 11,000,000 shares of its common stock at a price to the public of $9.00 per share. the gross proceeds from the offering to aura are expected to be $99.0 million, before deducting underwriting discounts and commission.
Latest News
2023-10-31 16:05:00 - Business Wire
Aura Biosciences to Present Updated Phase 2 Data Evaluating Suprachoroidal Administration of Belzupacap Sarotalocan (Bel-sar) for the First-Line Treatment of Patients with Early-Stage Choroidal Melanoma at AAO 2023
BOSTON--(BUSINESS WIRE)--Aura Biosciences Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications, today announced that updated data from the Phase 2 trial evaluating the safety and efficacy of suprachoroidal (SC) administration using its first VDC product candidate, bel-sar, for the first-line treatment of adult patients with early-stage choroidal melanoma will be presented at the upcomi.
2023-05-27 08:00:00 - Seeking Alpha
Aura Biosciences: Excellent Execution In The Large Ocular Cancer Market
AURA has solid phase 2 data for a very interesting molecule in primary choroidal melanoma. This indication has no approved therapies, no major pipeline development, and many US/EU patients.
2023-02-10 06:03:00 - The Motley Fool
Why Shares of Aura Biosciences Jumped This Week
The clinical-stage biotech may be ready to release updated phase 3 trial results on its lead therapy.
2022-09-27 07:00:00 - Business Wire
Aura Biosciences to Present Ongoing Phase 2 Data Evaluating Suprachoroidal Administration of Belzupacap Sarotalocan (AU-011) for the First-Line Treatment of Patients with Early-Stage Choroidal Melanoma at AAO 2022
BOSTON--(BUSINESS WIRE)--Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications, today announced that data from the ongoing Phase 2 trial evaluating the safety and efficacy of suprachoroidal (SC) administration using its first VDC product candidate, belzupacap sarotalocan (AU-011), for the first-line treatment of patients with early-stage choroidal melanoma [indetermina
2022-07-19 15:06:04 - Benzinga
JMP Is Bullish On This Cancer Stock "Sees New Way to Treat Cancer"
JMP Securities has initiated the coverage on Aura Biosciences Inc (NASDAQ: AURA) with a Market Outperform rating and a $26 risk-adjusted price target. Aura is developing a targeted virus-like drug conjugate (VDC) technology platform that could establish a new standard of.
2022-06-23 08:56:05 - Benzinga
Aura Biosciences' Belzupacap Sarotalocan At Par With Plaque Radiotherapy In Eye Cancer
Aura Biosciences Inc (NASDAQ: AURA) reported data from a retrospective analysis that assessed the visual acuity after plaque radiotherapy treatment compared with prospective data in early-stage choroidal melanoma patients treated with belzupacap sarotalocan by intravitreal.
2022-06-17 07:00:00 - Business Wire
Aura Biosciences to Present Updated Belzupacap Sarotalocan (AU-011) Data on Multiple Studies at the International Society of Ocular Oncology 2022 Bi-Annual Meeting
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Aura Biosciences Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications, today announced multiple presentations of data evaluating its first VDC, belzupacap sarotalocan (AU-011), for the first-line treatment of patients with early-stage choroidal melanoma (indeterminate lesions and small choroidal melanoma (CM)). The presentations include updated safety
2022-05-03 07:00:00 - Business Wire
Aura Biosciences to Present at the 2022 Bank of America Healthcare Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Aura Biosciences Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications, today announced that Elisabet de los Pinos, PhD, Chief Executive Officer of Aura will present at the 2022 Bank of America Healthcare Conference. The conference is being held in Las Vegas, Nevada and the presentation will take place on Tuesday, May 10, 2022, at 4:55 p.m. PT. A live
2022-02-14 17:00:00 - Business Wire
Aura Biosciences to Present Preclinical Data Demonstrating Applicability of AU-011 in Bladder Cancer at the 2022 ASCO Genitourinary Cancer Symposium
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Aura Biosciences Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications, today announced the presentation of preclinical data for its first VDC product candidate, AU-011, which is being developed for the treatment of Non-Muscle Invasive Bladder Cancer (NMIBC). The results will be presented as part of the 2022 American Society of Clinical Oncology (ASCO)
2021-10-30 23:43:00 - Seeking Alpha
U.S. IPO Weekly Recap: Semiconductors And Energy Storage Lead A Spooky 14 IPO Week
The IPO market remained active this past week as 13 IPOs raised $6.3 billion. SPAC activity kept steady with 13 blank check IPOs raising $2.1 billion.